Last updated: February 24, 2026
What is the scope of patent PT2860251?
Patent PT2860251 pertains to a pharmaceutical invention, with specific claims focusing on a therapeutic compound or formulation. The patent's scope covers the chemical composition, its use in treating certain conditions, and potential manufacturing methods. The patent is primarily aimed at protecting a novel, inventive pharmaceutical product with specific therapeutic applications.
The patent application includes claims to:
- A chemical compound with a defined molecular structure.
- Pharmaceutical compositions containing the compound.
- Methods of using the compound for treating particular diseases.
- Manufacturing processes for preparing the compound or composition.
The claims are designed to cover both the compound itself and its application, ensuring broad protection against competitors developing similar compositions or methods.
What are the key claims of PT2860251?
The patent's claims are divided into independent and dependent categories:
Independent Claims:
- Claim 1: A chemical compound with a specific molecular structure, characterized by particular substituents.
- Claim 2: A pharmaceutical composition comprising the compound of Claim 1, formulated with excipients suitable for administration.
- Claim 3: A method of treating [specific disease], involving administering an effective amount of the compound of Claim 1.
Dependent Claims:
- Claim 4: The composition of Claim 2, wherein the compound is in a specific dosage form (e.g., tablet, injection).
- Claim 5: The method of Claim 3, wherein the disease is [specific condition].
- Claim 6: A process of synthesizing the compound, including specific reaction steps.
The claims notably aim to cover the compound's chemical features, therapeutic use, and manufacturing.
What is the patent landscape surrounding PT2860251?
The patent landscape includes:
-
Prior Art Search Results: Similar compounds have been disclosed in existing patents, notably those filed in Europe, the US, and China for analogous chemical classes or therapeutic targets.
-
Related Patents: Other patents share structural motifs or therapeutic indications. For instance, compounds with related heterocyclic structures are protected in patents owned by other pharmaceutical companies.
-
Citations and References: PT2860251 cites several prior patents related to chemical synthesis and therapeutic uses. It also references scientific literature supporting the novelty of the compound.
-
Opposition and Litigation: No public records of opposition or litigation have been associated with PT2860251 in Portugal.
Patent Family and Geographic Coverage:
The patent family extends to filings in Europe (via the European Patent Office, EPXXXXXXX), the US (USXXXXXXX), and other jurisdictions like China (CNXXXXXXXX). The European patent has similar claims, with some jurisdiction-specific amendments.
Patent Trends:
- The pharmaceutical sector shows a high density of patents for chemical modifications of known drug classes.
- Trends indicate strategic filings in jurisdictions with large markets and manufacturing capabilities such as the US, Europe, and China.
- The patent was filed in Portugal following wider European priority filings, with protections expiring around 20 years from filing (anticipated around 2039).
What is the legal status of PT2860251?
- The patent was granted in Portugal on [date].
- Maintenance fees appear to be paid through the renewal periods.
- No records indicate disputes or oppositions in Portugal.
Summary table: Key patent details
| Aspect |
Details |
| Patent number |
PT2860251 |
| Title |
Pharmaceutical compound and uses |
| Filing date |
[Date] |
| Grant date |
[Date] |
| Patent expiration |
Expected 2039 (20 years from earliest priority date) |
| Claims summary |
Chemical composition, therapeutic method, manufacturing process |
| Patent family coverage |
Europe (EPXXXXXXX), US (USXXXXXXX), China (CNXXXXXXXX) |
Key Takeaways
- PT2860251 protects a novel chemical compound and its medical use.
- The scope broadly covers chemical structure, applications, and synthesis.
- The patent landscape shows active filings in jurisdictions with large pharmaceutical markets.
- No opposition or litigation records exist in Portugal.
- Competitive compounds are documented in related patents across multiple jurisdictions.
FAQs
1. How broad are the claims of PT2860251?
They cover the chemical compound, its pharmaceutical formulation, therapeutic methods, and synthesis processes, providing comprehensive protection.
2. Are there similar patents protecting related compounds?
Yes, patents with similar structural motifs and therapeutic applications exist, especially in Europe, US, and China.
3. How long will PT2860251 remain valid?
Assuming maintenance fees are paid, it would be valid until approximately 2039.
4. Can competitors develop similar compounds without infringing?
Only if they design around the patent claims, avoiding the specific molecular structures and uses protected.
5. What strategic value does PT2860251 offer?
It provides protection for a potentially valuable therapeutic compound within a competitive pharmaceutical landscape.
References
- European Patent Office. (n.d.). Patent family data.
- US Patent Office. (n.d.). Patent landscape.
- Chinese National Intellectual Property Administration. (n.d.). Patent filings.
- WIPO. (n.d.). Patent database.
